EPISODE · Apr 23, 2021 · 8 MIN
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
from Oncology Learning Network · host HMP Global
Nakia Spencer, Associate Scientist, MD Anderson Cancer Center, discusses the ongoing clinical trial of asparagine synthetase (ASNS) expression predicting response to the GLS1 inhibitor IPN60090 in ovarian cancer, through selective modulation of redox homeostasis, presented at the 2021 AACR Annual Meeting.
Embed this episode
Ready to play
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
0:00
8:11
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Learning Network?
This episode is 8 minutes long.
When was this Oncology Learning Network episode published?
This episode was published on April 23, 2021.
Can I download this Oncology Learning Network episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!